



(51) International Patent Classification:

C07K 14/56 (2006.01) C07K 19/00 (2006.01)
C07K 14/54 (2006.01) A61K 38/21 (2006.01)
C07K 14/55 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/020492

(22) International Filing Date:

16 March 2022 (16.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/161,913	16 March 2021 (16.03.2021)	US
63/164,827	23 March 2021 (23.03.2021)	US
63/254,748	12 October 2021 (12.10.2021)	US
63/276,893	08 November 2021 (08.11.2021)	US

(71) Applicant: **CYTOX THERAPEUTICS, INC.**
[US/US]; 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US).

(72) Inventors: **MITRA, Sayantan**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **LAPUYADE, Nicole G.**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite

400, South San Francisco, California 94080 (US). **ASSI, Hikmat Haizar**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **PAIDHUNGAT, Madan M.**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **DANIEL, Dylan L.**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **LE SCOLAN, Erwan**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **BOGDANOFF, Walter A.**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **CAI, Na**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **WANG, Hsin**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). **BEREZHNOY, Alexey Yevgenyevich**; c/o CytomX Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: MASKED ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS




FIG. 1

(57) Abstract: Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*